

From: [OC GCP Questions](#)
To: [REDACTED]
Subject: Part 11 and Sponsor-Investigator Trials
Date: Monday, May 11, 2015 10:56:38 AM

Good morning –

Any electronic records in a FDA-regulated clinical trial (sponsor only or sponsor-investigator) should be Part 11 compliant except EMRs.

The guidances listed below might be helpful to you.

Part 11 –Electronic Records --

<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126953.pdf>

Computerized Systems Used in Clinical Investigations –

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070266.pdf>

Electronic Source Data in Clinical Investigations –

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328691.pdf>

This document includes information related to the creation and maintenance of electronic case report forms(eCRF). It describes and electronic medical record (EMR) as a possible data originator for an eCRF. However, section IV. of the document states that, although adequate controls need to be in place to ensure confidence in the reliability, quality and integrity of electronic source data, performance standards for EMRs may be regulated by other authorities and FDA does not intend to assess compliance of EMRs with part 11.

I hope this information is helpful. Please contact us again at gcp.questions@fda.hhs.gov for additional questions.

Kind regards,

Doreen M. Kezer, MSN
Senior Health Policy Analyst
Office of Good Clinical Practice
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: [REDACTED]
Sent: Friday, May 08, 2015 4:32 PM
To: OC GCP Questions
Subject: Part 11 and Sponsor-Investigator Trials

Dear FDA,

Do you expect sponsor investigators to adhere to part 11 compliance with regard to the management of their multi-site studies?

Sincerely,

[REDACTED]